tbuckley/cabot-search huggingface dataset:
Intrapleural instillation of quinacrine for recurrent pneumothorax. Use in a patient with cystic fibrosis
Authors: J. Kattwinkel
Journal: JAMA (1973)

Intrapleural instillation of quinacrine hydrochloride was used to treat recurrent bilateral pneumothorax in a 29-year-old man with advanced pulmonary disease from cystic fibrosis. For 23 months and 11 months following intrapleural instillation of quinacrine into the left and right lungs, respectively, there was no recurrence of pneumothorax on either side. Death was due to pulmonary failure, and at autopsy there were dense adhesions completely obliterating the pleural spaces. This mode of therapy may provide a valuable alternative to surgery for the cystic fibrosis patient with severe lung disease and marginal pulmonary reserve.
Lymphoma
Authors: Marian Steele
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pills and Proverbs
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pesticide poisoning in children
Authors: A. E. DePalma
Journal: JAMA (1970)

Two siblings were poisoned with parathion, chlordane, and dimpylate (Diazinon) when they ingested the contents of an unlabeled jar. One of the children died despite atropine sulfate and pralidoxime chloride therapy. The patients had the highest serum gastric contents and tissue levels of parathion, chlordane, and dimpylate ever recorded, to our knowledge. The onset of symptoms was rapid and progressed quickly to coma and convulsions. Cardiac arrest occurred in the fatal case. Blood cholinesterase levels were markedly decreased in both patients, and urine paranitrophenol levels remained elevated for more than a week in the survivor. The danger of removing a toxic substance from its original container and placing it elsewhere is obvious. Rapid, aggressive, and specific therapy for organophosphate poisoning must be instituted even before diagnosis is confirmed by laboratory procedures.
I have recently joined as a staff grade in obstetrics and gynaecology for 12 sessions a week. I want to know how many sessions for administration, study, teaching, CPD, special interest, non-clinical commitments that staff grades are entitled to. What are the rules regarding prospective cover, and should I be paid for an extra session if I am working for 12 sessions? Is there any compensation for the prospective cover?
Authors: Romeh Gupta
Journal: BMJ (2006)

Have a career or related problem that needs answering? Can9t find the right person to point you in the right direction? Log on to the Advice Zone for reliable medical careers advice. You can post a question or see if one of our 300 advisers has already answered a similar question. Here is a selection of questions and answers posted on the site. <b>www.bmjcareers.com/advicezone</b>
Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department
Authors: E M Skobeloff, W H Spivey, R M McNamara, L Greenspon
Journal: JAMA (1989)

Conventional nebulized β-agonist therapy has met with disappointing results in an increasing number of moderate to severe asthmatics who may be characterized as "poor responders." Thirty-eight patients suffering from acute exacerbations of moderate to severe asthma were treated in an emergency department with an intravenous infusion of saline placebo or 1.2 g of magnesium sulfate after conventional β-agonist therapy failed to produce significant improvement in peak expiratory flow rate. Nineteen patients were randomized into each of two groups in a placebo-controlled, double-blind clinical trial. The treatment group demonstrated an increase in peak expiratory flow rate from 225 to 297 L/min as compared with 208 to 216 L/min seen in the placebo group. In addition, the number admitted vs discharged was significantly better for the treatment group (7 vs 12) than the placebo group (15 vs 4). Intravenous magnesium sulfate may represent a beneficial adjunct therapy in patients with moderate to severe asthma who show little improvement with β-agonists. (<i>JAMA</i>. 1989;262:1210-1213)
Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).
Authors: Tamas Pinter, Steve Abella, Alvydas Cesas, Adina Croitoru, Jochen Decaestecker, Peter Gibbs, Yevhen Hotko, Jacek Jassem, Galina Petrova Kurteva, Jan Novotny, Seamus O'Reilly, Tomas Salek, May F. Mo, L. Mi Rim Choi, Charles Davic Blanke
Journal: Journal of Clinical Oncology (2013)

LBA445 Background: The literature reports that adding biologics to chemotherapy (ctx) may increase the incidence of clinically significant neutropenia. This trial was conducted to evaluate the efficacy of PEG in reducing the incidence of febrile neutropenia (FN) in pts with locally advanced (LA) or metastatic (m)CRC receiving first-line treatment with either FOLFOX/B or FOLFIRI/B. Methods: Key eligibility: ≥ 18 years old; measurable, nonresectable CRC per RECIST 1.1. Pts were randomly assigned 1:1 to either placebo or 6 mg PEG ~24 h after ctx/B. The study treatment period included four Q2W cycles, but pts could continue their assigned regimen until progression. Pts were stratified by region (North America vs rest of world), stage (LA vs mCRC), and ctx (FOLFOX vs FOLFIRI). Estimated sample size (N = 800) was based on the expected incidence of grade 3/4 FN (primary endpoint) across the first 4 cycles of ctx/B, powered for PEG superiority over placebo. Other endpoints included overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results: 845 pts were randomized (Nov 2009 to Jan 2012) and received study treatment; 783 pts completed 4 cycles of ctx/B. Median age was 61 years; 512 (61%) pts were male; 819 (97%) had mCRC; 414 (49%) received FOLFOX, and 431 (51%) received FOLFIRI. Grade 3/4 FN (first 4 cycles) for placebo vs PEG was 5.7% vs 2.4%; OR 0.41; p = 0.014. A similar incidence of other ≥ grade 3 adverse events was seen in both arms (28% placebo; 27% PEG). See Table for additional results. Conclusions: PEG significantly reduced the incidence of grade 3/4 FN in this pt population receiving standard ctx/B for CRC. Follow-up is ongoing. Clinical trial information: NCT00911170. [Table: see text]
Consumption: Its Prevention and Home Treatement.
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Thrombolytic Therapy
Authors: Glenn L. Laffel, Eugene Braunwald
Journal: New England Journal of Medicine (1984)

ComplicationsThe most common complications of streptokinase-mediated reperfusion are myocardial and systemic hemorrhage and reperfusion arrhythmias. Hemorrhagic infarction has been reported in patients who died after receiving streptokinase therapy for acute myocardial infarction.69 In these patients, as in laboratory animals, hemorrhage is confined to the area of myocellular necrosis. Hemorrhagic infarction undoubtedly also occurs in streptokinase-treated survivors of acute myocardial infarction, and there is no evidence that it has a detrimental effect on the outcome of infarction.In properly selected patients,34 hemorrhagic complications are generally confined to hematoma formation at the site of arterial punctures and localized oozing at venipuncture . . .
Inactivation of Polycomb Repressive Complex 2 Components in Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms
Authors: Nicholas C.P. Cross, Joannah Score, Claire Hidalgo-Curtis, Amy V Jones, Nils Winkelmann, Alison Skinner, Daniel Ward, Katerina Zoi, Thomas Ernst, Frank Stegelmann, Konstanze Dohner, Andrew J Chase
Journal: Blood (2011)
Visiting Dave
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
State Medical Licensing Board Requirements for Residents
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
What should be done now that national health system reform is dead?
Authors: R. J. Blendon
Journal: JAMA (1995)

The demise of the movement toward major federal health system reform legislation leaves us facing two stark realities. First, many of the widely recognized problems of our health care system will remain with us. Second, the failure of our political system, after 2 years of public and legislative debate, to enact any version of comprehensive legislation suggests it is unlikely to do so in the near future. This legislative impasse has major implications for what will happen in the years ahead. See also p 242. We highlight briefly the problems we expect to persist as a result of the national failure to develop comprehensive reform. We then suggest alternative strategies for incremental reform, distinguishing between those issues easily and those not so easily resolved in our emerging political environment. We can expect in the near term the following: The number of Americans without health insurance will remain high. Just last
The First Step
Authors: Priya Misra
Journal: JAMA Cardiology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Nanoparticular bisphosphonate induces an anti-fibrotic response by modulation of fibrosis associated genes and pathways in (non-) parenchymal liver cells in CCL4 fibrotic mice
Authors: Leonard Kaps, Lutz Nuhn, Niklas Choteschovsky, Friedrich Foerster, Mustafa Diken, Adrian Klefenz, Detlef Schuppan
Journal: Journal of Hepatology (2020)
The medium term findings in coronary arteries by intravascular ultrasound in infants and children after heart transplantation
Authors: M.A. Kuhn, K.R. Jutzy, S.D. Fritzsche, C.E. Cephus, D.D. Derning, L.L. Bailey, R.E. Chinnock, R.L. Larsen
Journal: Journal of the American College of Cardiology (1998)
Anesthesiology
Authors: Robert K. Stoelting
Journal: JAMA (1991)

Anesthesiology in 1990 benefited from the introduction of new drugs and the availability of new information to guide daily practice. Advances in pharmacology included the introduction or imminent development of drugs with therapeutic profiles likely to lead to the displacement of currently used drugs. For example, a nonopioid analgesic lacking ventilatory depressant effects is now available, and the long-sought goal to find a suitable replacement for nitrous oxide seems achievable. There is new information that adds to our understanding of drug-induced hepatotoxicity and the role, if any, of anesthetic drugs in the occurrence of intraoperative myocardial ischemia. Traditional concepts, such as prolonged fluid fasting before the induction of anesthesia for elective operations, are being reconsidered, while the practice of administering potent opioids before a painful surgical stimulus is supported by previously unappreciated aspects of neurophysiology. Ketorolac J.X.etorolac tromethamine, a nonopioid antiinflammatory drug with analgesic effects equivalent to morphine, was introduced
Effect of Lung Capacity and Content on Rate of Arterial Desaturation in Dogs
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Preface
Authors: James R. Baker
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Proc Soc Exper Biology &amp;amp; Medicine, New York
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland
Journal: Thorax (2008)

I am delighted to write the foreword for this consensus statement which updates the ''Recommendations on the management of pulmonary hypertension in clinical practice'' of 2001.The consensus statement reflects contemporary practice in the management of this uncommon, deadly but now treatable condition in the pulmonary hypertension designated centres in the UK and Ireland.It matches and complements international guidelines, which are currently under revision.In addition to health professionals who encounter affected patients within national centres or in other fields of practice, the statement is a comprehensive but readily accessible source of information for commissioners and managers of specialised services.Initially the evidence on which to base the care of patients with rare and deadly diseases often rests on the experience and judgement of those who deliver daily care, the collection of clinical, epidemiological and pathological data, and the assiduous construction of informative registers.This familiar discipline has enabled the advances summarised in this document.The first challenge to health service commissioners is to ensure that all patients with pulmonary hypertension have access to appropriate therapy as quickly as possible.Delay in making the diagnosis has the same consequences as delay in those with cancer.Regrettably ''postcode prescribing'' and its consequences still persist.As for other uncommon conditions, continued progress in developing effective therapies rests on specialised centres working in concert to develop and participate in well-designed clinical trials, particularly trials of combination therapy.This statement is a testament to the major advances in therapy made over the last 10 years, progress those of us who have cared for such patients over more than 30 years could not have envisaged.